AstraZeneca Could Have Avoided a £19 Billion Loss with BVCT.
BVCT sealed its eplontersen call (No. 1863) on : technical partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in CV mortality/CV recurrence compared with SoC alone (tafamidis)). CARDIO-TTRansform missed its primary endpoint; the dashboard classifies the readout as True Negative (TN), 574 days after the call.
BVCT sealed the call 574 days before the primary endpoint miss.
On , AstraZeneca and Ionis announced that CARDIO-TTRansform — the largest enrolled ATTR-CM Phase 3 trial on record — failed to meet its primary endpoint of composite CV mortality and recurrent CV events compared with placebo. In the subgroup of patients on stabilizer therapy (e.g., tafamidis) at baseline: no effect was observed. AstraZeneca’s market value fell by an estimated £19 billion in a single day, according to IG UK.
BeatSoC Virtual Clinical Trial (BVCT) had sealed this call on — 574 days earlier. BVCT’s proprietary ATTR-CM virtual patients reliably predicted this outcome by simulating the underlying drug-body causal mechanisms. No patient data were ingested. In our view, the £19 billion was avoidable.
All it would have taken was 7 days and BVCT’s prospective clinical derisking — at less than 0.1% of the cost of running a 1,432-patient, 130-site, 140-week global Phase 3 trial (trial size as reported by AstraZeneca).
BVCT called eplontersen in ATTR-CM statistically maybe significant yet at most weak additive clinical benefit vs. tafamidis (HR > 0.8) — 574 days before the data confirmed it at a cost of £19 billion. As recorded on the dashboard, the technical call reads partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in CV mortality/CV recurrence compared with SoC alone (tafamidis)) and the commercial call partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in 6MWT/KCCQ/all-cause mortality at most weakly superior to SoC alone (tafamidis)). The dashboard classifies the readout as True Negative (TN).
partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in CV mortality/CV recurrence compared with SoC alone (tafamidis))
Commercial Prediction
partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in 6MWT/KCCQ/all-cause mortality at most weakly superior to SoC alone (tafamidis))
What It Cost. What It Would Have Cost to Know.
CARDIO-TTRansform — Proceeding Without BVCT
Trial scale
1,432 patients · 130 sites · 20 countries · 140 weeks (AstraZeneca; ClinicalTrials.gov lists 1,438 enrolled at 139 locations)
Market value lost
~£19 billion (AZN, )
Advance derisking signal available
574 days earlier · BVCT call sealed
BVCT derisking cost
7 days · <0.1% of Phase 3 cost · before the readout
BVCT delivers a prospective, mechanistic, per-programme Phase 3 effect size call vs. your specified standard of care in one week — before Phase 3 commit, before IND-enabling spend, before patient enrollment. Specify your drug mechanism, the indication, the patient stratum, and the comparator SoC. Receive a quantified composite endpoint HR / OR / RR, a GO / NO-GO call, and a mechanistic causal rationale via a sealed, timestamped PandaDoc certificate. No patient data required. No ML training on past trial outcomes.
Your next RNA medicine programme. Derisk it in 7 days.